SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Upregulated PKM2 Protects Dopaminergic Neurons From Oxidative Damage Through Nrf2 Transactivation in an MPTP-Induced Mouse Model of Parkinson's Disease.

CNS Neurosci Ther · 2026-06-01

DOI: 10.1002/cns.70968PMID: 42226456

Open accessResearch Support, Non-U.S. Gov't; research-article; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundThe death of dopaminergic neurons in the substantia nigra pars compacta (SNc) is the core defining pathological change of Parkinson's disease (PD). We previously showed that reducing neuronal pyruvate kinase M2 (PKM2) aggravates oxidative damage and accelerates dopaminergic neuron loss, although the mechanism remained unclear.MethodsIn the MPTP mouse model, we evaluated antioxidant responses and neuronal survival after selectively deleting PKM2 in dopaminergic neurons or overexpressing PKM2. In MPP+-treated primary neurons, we examined how ROS influences hnRNP A1/A2 and alternative splicing toward PKM2, and we tested reversibility by knocking down hnRNP A1/A2 or scavenging ROS.ResultsNeuronal PKM2 knockdown abolished MPTP-induced activation of Nrf2 target genes, exacerbated lipid peroxidation and DNA damage, and accelerated loss of dopaminergic neurons, whereas PKM2 overexpression restored the antioxidant response and mitigated neurodegeneration. Mechanistically, ROS generated by MPP+ increased hnRNP A1/A2, promoting alternative splicing toward PKM2 and elevating its abundance; conversely, hnRNP A1/A2 knockdown or ROS scavenging reversed this splicing shift and attenuated the antioxidant response.ConclusionThese findings delineate a signaling pathway in which ROS elevate hnRNP A1/A2, favor PKM2 production, and activate Nrf2, thereby providing a mechanistic basis for the oxidative injury and progressive dopaminergic neuron degeneration observed with PKM2 loss. The PKM2-Nrf2 axis thus emerges as a candidate target for disease-modifying therapy in PD.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.